RISE registry reveals potential gaps in medication safety for new users of biologics and targeted synthetic DMARDs

. Author manuscript; available in PMC: 2021 Dec 1.

Published in final edited form as: Semin Arthritis Rheum. 2020 Mar 19;50(6):1542–1548. doi: 10.1016/j.semarthrit.2020.03.003

	HBV	TB	HBV and TB composite measure
Primary analysis^*	7731 (28.8)	7117 (29.7)	4157 (15.5)
Sensitivity analysis 1^†	8794 (32.8)	9813 (40.9)	5559 (20.7)
Sensitivity analysis 2^**	9143 (34.1)	15231 (63.5)	7784 (29.0)

Primary analysis: HBV (Hepatitis B virus) testing was required to have occurred at any time prior to the index date; TB (tuberculosis) testing was required in the 12 months prior to the index date.

^†

Sensitivity analysis 1: for HBV, this window was defined as any time prior to the index date through 60 days after the index date; for TB testing, this window was defined as 12 months prior to the index date through 60 days after the index date.

^**

Sensitivity analysis 2: for all tests, we searched all available data, including both before and after the index date.